Mecro

COVID-19 ART (Assisted Real-time Test)

Blockchain Diagnostic Kit Platform



Index

1. Coronavirus disease (COVID-19) Outbreak 3 page

2. MECRO CHAIN 4 page

3. COVID Response from Major Countries 5 page

4. Status of COVID Diagnostic Services at Domestic and abroad 7 page

5. COVID-19 Vaccine Development Trends 10 page

6. MEC CHAIN Platform 17 page

7. TEAM 22 page

8. LEGAL DISCLAIMERS 23 page

I.
Coronavirus disease (COVID-19) Outbreak



COVID-19, Declares Pandemics 73 Days After Occurrence

On 11 March 2020 (local time), the World Health Organization (WHO) declared a Pandemic for COVID-19. It has been 73 days since the new coronavirus was reported. In the meantime , COVID -19 has infect 116,308 people and killed 4,548 people in 66 countries worldwide (as of March 11).

WHO Declares PHEIC on COVID-19 January 30

COVID -19 began in December 2019 with the occurrence of a patient with an unknown cause in Wuhan , Hubei Province , China . It was officially reported on December 31, and the WHO announced that the pneumonia was caused by a variant of the coronavirus . The Chinese government decided to shut down Wuhan City to prevent the spread of confirmed and confirmed deaths, and the WHO convened an emergency meeting on January 30 to declare a PHEIC - Public Health Emergency of International Concern . PHEIC should be at least two of the 4 cases in which 1) the impact on public health is severe, 2) the event is unusual or unexpected, 3) the risk of inter-country propagation is high, 4)the risk of restricting international trade or traffic. A total of six cases have been declared so far, including the Swine flu in 2009, the Middle East Polio virus in 2014, the West African Ebola virus, the Zika virus in 2015, and the Kibu Ebola virus in 2018.

The World Health Organization's Pandemic Declaration is the first, since the swine flu outbreak in 2009.

Infection in China , where the largest number of casualties occurred , and Korea , where the number of confirmed cases has been increasing rapidly , is decreasing . However, as the U.S. and Europe are rapidly spreading, global infections are feared. In response , WHO declared Pandemic for COVID -19. This is the first time since the pandemic of swine flu (H1N1pdm09), which killed more than 20,000 people worldwide in 2009 and 2010.

II.

MEC CHAIN

Background

As Korea's successful COVID response is regarded as a model case around the world, it has asked countries around the world to share their experiences. As a result, the international standardization was promoted by organizing the test - trace - treatment (treat) into the 3T 'K-prevention model' used in the all process of responding to infectious diseases. Despite the recommendations of many medical field experts and public demands , the quarantine authorities have not taken extreme measures such as a full-scale blockade . Instead , the rapid inspection through diagnostic kits , active infection tracking using IT platforms such as CCTV and mobile phone location information , and strong social distancing practices allowed the country to respond flexibly and quickly to the rapid development of the pandemic , making it more stable than other European countries.

15,000 diagnostics per day··· Introduction of 'emergency use approval system' after MERS

There is an 'emergency use approval system ' that allows the rapid distribution of diagnostic kits. This is a system in which the head of the Ministry of Food and Drug Safety approves diagnostic products that have not yet been approved and permits manufacturing , selling and using them temporarily . The Korean government , which suffered MERS (Middle East Respiratory Syndrome) in 2015, introduced the system in 2017. The problem, however , is that these diagnostics result data are managed and available in a safe, reliable state, to which we propose the introduction of blockchain technology.

III.

COVID Response from Major Countries

U.S. COVID-19 Response (CDC Manual)

- Preparing Emergency rescue workers, medical service providers and medical systems.
- Provide advice for businesses, communities and schools.
- Protect the health of travelers and communities in the mobile system around the world.

Eurozone COVID-19 Response



Germany's death rate is about 11.5 per 100,000 people, but neighboring Belgium's death rate is 87 per 100,000 people, more than seven times higher. France has 48 per 100,000 people and Britain has 63.3 per 100,000 people. All four countries mentioned above are considered relatively wealthy and have good health systems.

The quarantine measures taken to prevent the spread of COVID-19 are similar. It used the blockade, social distancing , and personal hygiene regulations.

Japan COVID-19 response

Not only did it not declare an emergency again, but it is also implementing a policy called "Go To Travel" that compensates for domestic travel costs, saying it will boost domestic consumption. The plan is aimed at preventing the spread of COVID-19 while normalizing economic activities, but the increase in the number of confirmed people seems to have significantly yielded quarantine measures to stimulate the economy.

3. COVID Response from Major Countries

COVID-19 Policy Directions and Proposition Background

- In order to prevent the collapse of the epidemiological investigation and the infrastructure for treating infectious diseases, mass production of diagnostic kits and self-inspection are allowed on the premise that test results are quickly derived.

- Self-diagnosis, utilization of IT technology, active use of personal information, and personal information protection measures need to be established to share and utilize the results of rapid diagnostic testing and inspection.

- For faster inspection systems, environment, and epidemiological investigations than the spread of infectious diseases, conventional expression-oriented testing, manual testing, and centralized testing are excluded.

- Increasing and segmenting test standards is a hindrance to ensuring self-determination for ordinary medical practitioners to participate in diagnostic tests
(Cost, convenience and reliability must be above a certain level to ensure self-determination.)

- Suggestion to conduct a nationwide diagnostic kit inspection
 ·Survey the positive rate with a large antibody survey and trace the asymptomatic local infected person
·Quick diagnosis kit cost 1,000 won and total cost 50 billion won for 50 million people inspection
·It is carried out 10 times ten month once a month for 10 months. Total inspection is 500 million times and total inspection cost is 500 billion won.
(Example: KRW 900 billion is sufficient for communication/vaccine support out of the 20 extra budgets.)

Ⅳ.

Status of COVID Diagnostic Services at Domestic and abroad

As the pandemic of COVID -19 has been declared , attention is being paid to the diagnosis , treatment , and prevention of the new COVID-19. The situation is very different from SARS-CoV-2 in 2002 and MERS in 2012. SARS and MERS have so far been absent from pharmaceutical companies' attention as the number of patients has dropped sharply after the epidemic. But COVID-19 is different. This is because as the world experiences the pandemic, it is predicted that people will have to vaccinate and take treatments every year like the flu.



Regulators of governments around the world have implemented a system to prepare for the pandemic of infectious diseases and are especially active in responding to the diagnosis of COVID-19. At the request of the Centers for Disease Control and Prevention (CDC), the FDA announced the Emergency Use Authorization (EUA), which promotes the development and review of products for diagnosis, treatment and prevention of COVID-19. The EUA is a bill that uses possible medical countermeasures (MCM) in situations where new infectious diseases and public health are threatened by chemical, biological, radiological, and nuclear (CBRN). Under EUA, the Director -General of the FDA may authorize the use of unauthorized medicines and medical devices in emergencies. EUA follow FD&C article 564 of FDA, and amended following Project Bioshield Act in 2004, Pandemic and All-Hazards Preparedness Reauthorization Act(PAHPRA) in 2013, 21st century Cures Act in 2016 and Public Law 115-92 in 2017. Currently , there are a total of nine EUA diseases , six of which are related to the diagnosis of infectious diseases. The species include avian influenza H7N9 (2013), MERS (2013), Ebola virus (2014), Enterovirus (2015), Zika virus (Zika virus), and COVID-19.

4. Status of COVID Diagnostic Services at Domestic and abroad

The FDA granted emergency use approvals for a total of 16 diagnostic kits by March 24 after applying the EUA to COVID-19. Products are all based on RT-PCR, CDC (February 4), Wadsworth Center & NYSDOH(February 29), Roche(March 12), Thermo Fisher(March 13), Hologic, LapCorp(March 16), Quidel, Quest Diagnostics(March 17), Abbott(March 18), DiaSorin, GenMark(March 19), Primerdesign , Cepheid(March 20), BioFire Defense, Mesa(March 23), PerkinElmer(March 24) products listed above are proved and used. The FDA also announced a policy to simplify the confirmation method on February 29. This was primarily improved to allow state-certified medical institutions to make confirmations in existing systems that require diagnosis by local medical institutions and confirmation by the Centers for Disease Control and Prevention, enabling rapid diagnosis of the symptoms. And on March 16, FDA announced a policy to enable the use of immunodeficiency diagnosis that is somewhat less accurate than RT-PCR but can be diagnosed quickly.

4. Status of COVID Diagnostic Services at Domestic and abroad

In Korea, the government implements an emergency use approval system that permits the temporary use of medical devices , including diagnostic reagents , if there are no products approved in Korea or supply is insufficient during the pandemic. On January 28, the Korea Centers for Disease Control and Prevention received applications from companies through the "Application for Evaluation of New CoronaVirus Genetic Test Reagent" and 64 applications were filed until February 28, with five companies – Kogene Biotech , Seegene , Solgent , Sdbiosensor and Biosewoom – receiving approval so far. It is expected that the number of products that are approved for emergency use will increase as the number of companies that have applied is not small and there are many companies under review.

V.
COVID-19 Vaccine Development Trends

According to WHO, there are 176 candidates as of August 28th. Of the 176 units, 143 are in the preclinical phase and 33 are in clinical trials.

5.1 Vaccine development process

Vaccines, unlike regular drugs, prevent diseases in healthy people rather than treat them. However, vaccines and drugs go through similar clinical trials. Vaccine candidates pass a total of four stages for permission, including 1) preclinical phase, 2) clinical trial 1, 3) clinical trial 2, 4) clinical trial 4.

The predecessor of the "Animal Test" evaluates the safety of vaccine candidates and the effect of inducing immunogenicity and immune response through tissue culture, cell culture and animal testing. The predecessor is mainly performed on mice and monkeys. Most vaccine candidates fail to enter the first phase of clinical trials because they fail to produce immune responses in their predecessor stages. The full-time phase takes one to two years on average.

Clinical phase I, which evaluates 'safety', inoculates people on a small scale to establish a safe dose of the developed vaccine. If the vaccine passes immunogenicity and toxicity standards in clinical phase 1, phase 2 of clinical trials that "extend" and extend research begins. Phase 2 of the clinical trial includes approximately 300 participants and classifies the participants according to their characteristics to examine the safety of the vaccine. Clinical 1 and 2 phase is a method of combining phase 1 and phase 2 to accelerate development.

The third phase of clinical trials confirming "effectiveness" is a large-scale study that inoculates up to 3,000 vaccine candidates who have been successful in the second phase. The third phase of clinical trials compares and analyzes people who vaccinate with placebo through a large-scale random double-blind study to examine whether vaccine candidates are safe for many people and whether they are effective in preventing diseases. If a vaccine candidate successfully passes the previous, first, second, and third prizes, he or she will receive permission from the health authorities.

5.2 Current Status of Major Corona19 Vaccine Candidates

주요 코로나19 백신 후보 개발 현황 (기준: 2020년 8월 28일)

개발사제조업체	백신 플랫폼	접종도즈	투여법	임상시험 단계				
				1상	1/2상	2상	3상	승인
University of Oxford/AstraZeneca	Non-Replicating Viral Vector	1	IM					
CanSino Biological Inc. /Beijing Institute of Biotechnology	Non-Replicating Viral Vector	1	IM					
Gamaleya Research Institute	Non-Replicating Viral Vector	2	IM					
Sinovac	Inactivated	2	IM					
Wuhan Institute of Biological Products/Sinopharm	Inactivated	2	IM					
Beijing Institute of Biological Products/Sinopharm	Inactivated	2	IM					
Moderna/NIAID	RNA	2	IM					
BioNTech/Fosun Pharma/Pfizer	RNA	2	IM					
Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences	Protein subunit	2~3	IM					
Curevac	RNA	2	IM					
Institute of Medical Biology, Chinese Academy of Medical Sciences	Inactivated	2	IM					
Research Institute for Biological Safety Problems, Kazakhstan	Inactivated	2	IM					
Inovio Pharmaceuticals/ International Vaccine Institute	DNA	2	ID					
Osaka University/ AnGes/ Takara Bio	DNA	2	IM					
Cadila Healthcare Limited	DNA	3	ID					
Genexine Consortium	DNA	2	IM					
Bharat Biotech	Inactivated	2	IM					
Janssen Pharmaceutical Companies	Non-Replicating Viral Vector	2	IM					
Novavax	Protein subunit	2	IM					
Kentucky Bioprocessing, Inc	Protein subunit	2	IM					
Arcturus/Duke-NUS	RNA	2	IM					
ReiThera/LEUKOCARE/Univercells	Non-Replicating Viral Vector	1	IM					
Clover Biopharmaceuticals Inc. /GSK/Dynavax	Protein subunit	2	IM					
Vaxine Pty Ltd/Medytox	Protein subunit	1	IM					
University of Queensland/CSL/Seqirus	Protein subunit	2	IM					
Medigen Vaccine Biologics Corporation/NIAID/Dynavax	Protein subunit	2	IM					
Instituto Finlay de Vacunas, Cuba	Protein subunit	2	IM					
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo	Protein subunit	2	IM					
West China Hospital, Sichuan University	Protein subunit	2	IM					
Institute Pasteur/Themis/Univ. of Pittsburg CVR/MSD	Replicating Viral Vector	1~2	IM					
Imperial College London	RNA	2	IM					
People's Liberation Army Academy of Military Sciences/Walvax Biotech	RNA	2	IM					
Medicago Inc.	VLP	2	IM					

5.3 Pharmaceutical company that started phase 3 clinical trials

Followings are Pharmaceutical companies that started Phase III clinical trials.

✓ Moderna, USA – National Institute of Allergies and Diseases (NIID)

✓ American Pfizer – includes BioNTech.

✓ AstraZeneca – University of Oxford

✓ Sinopharm, China



5.4 Category of vaccine platform

There are a total of seven types of vaccines. The most frequently developed type is the protein subunit.

5. COVID-19 Vaccine Development Trends

and ▲Inactive ▲ RNA (mRNA) ▲ Self-Replicating Viral Vector (RVV) ▲ DNA ▲Non-Replicating Viral Vector (NRVV) Viruses ▲Virus-Like Particles (VLP) based vaccines are being developed.

플랫폼	원리	사례
불활화	사멸된 바이러스를 이용해 면역체계를 강화함.	A형 간염, 독감 소아마비, 광견병
단백질 서브유닛	불활화 백신과 같이 사멸된 바이러스를 이용하지만 바이러스 항원을 부분적으로만 포함해 면역체계를 강화함.	헤모필루스 인플루엔자B, 대상포진 B형 간염, 인유두종바이러스(HPV)
DNA	바이러스의 유전자를 사용해 면역체계를 자극함.	없음
RNA	DNA와 단백질의 혼합한 백신으로 세포가 바이러스를 생산하도록 유도함.	없음
바이러스 벡터	살아있는 바이러스를 사용해 DNA를 세포로 운반함.	에볼라
VLP	바이러스 표면의 단백질과 같은 입자를 이용해 바이러스와 유사한 면역체계 반응 유도.	없음

5.4 Use

- Chaum Hospital

Chaum hospital (Chaum) is use of MECRO coin which have the character of medical coin.It is possible to use MECRO coin in Chaums' premium health check-up, power anti-aging specialized center and restaurant. Chaum aims prevention beyond treatment under the slogan of 'open to everyone'. To this end, Chaum uses various wisdom and skills such as exercise prescription and food treatment as well as Western medicine, Oriental medicine, and integrated medicine. So far, most patients have visited hospitals when the disease is revealed, but most people are in a state of "grey zone" that is neither healthy nor ill.

The purpose of Chaum is to check peoples' health and fill it in unhealthy conditions in this "grey zone." Chaum will be a pioneer in custom medicine through advanced solutions and a growth engine for future medicine. Chaum Hospital operates 12 specialized centers and tries to detect and prevent diseases early through customized medical care. Chaum also provides customized care through collaboration among medical staff.

Detox clinic, power anti-aging clinic, food therapy clinic, immunotherapy clinic, metabolic syndrome center, skin cosmetic clinic, slim clinic, neuromuscular center, postpartum clinic, evercell spa, hair spa, international medical center.

- Premium health check-up

Chaum Hospital can conduct basic tests on the following checks.

5. COVID-19 Vaccine Development Trends

- MEN

Basic test A (Under age 50)	prognosis, mental health questionnaire, nutrition counseling, results counseling, physical measurement and body composition analysis, blood pressure, urine test, stool test (substimulation, parasites), vision test, ophthalmic measurement, ophthalmic test, hearing test, lung function test, electrocardiogram, chest scan, general blood test (blood disease, anemia, inflammation), general chemical test (liver function, alcohol interstellar function, jaundice, kidney function, gout); hepatitis (type A,B,C), hyperlipidemia (neutral fat, cholesterol), diabetes, glycolytic pigmentation, insulin, insulin resistance, thyroid function, electrolyte, inflammation (ESR/CRP), amylase, rheumatoid factor, calcium, phosphorus (bone metabolism), vitamin D (calcium absorption), syphilis, AIDS, Tumor markers (pancreatic/colon/ liver/ prostate)
Basic test B (Over age 50)	prognosis, mental health questionnaire, nutrition counseling, results counseling, physical measurement and body composition analysis, blood pressure, urine test, stool test (substimulation, parasites), vision test, ophthalmic measurement, ophthalmic test, hearing test, lung function test, electrocardiogram, chest scan, general blood test (blood disease, anemia, inflammation), general chemical test (liver function, alcohol interstellar function, jaundice, kidney function, gout); hepatitis (type A,B,C), hyperlipidemia (neutral fat, cholesterol), diabetes, glycolytic pigmentation, insulin, insulin resistance, thyroid function, electrolyte, inflammation (ESR/CRP), amylase, rheumatoid factor, calcium, phosphorus (bone metabolism), vitamin D (calcium absorption), syphilis, AIDS, tumor markers (e.g. pancreas / colon / liver / prostate), bone density, prostate ultrasonography

WOMAN

Basic test A (Under age 45)	prognosis, mental health questionnaire, nutrition counseling, results counseling, physical measurement and body composition analysis, blood pressure, urine test, stool test (substimulation, parasites), vision test, ophthalmic measurement, ophthalmic test, hearing test, lung function test, electrocardiogram, chest scan, general blood test (blood disease, anemia, inflammation), general chemical test (liver function, alcohol interstellar function, jaundice, kidney function, gout); hepatitis (type A,B,C), hyperlipidemia (neutral fat, cholesterol), diabetes, glycolytic pigmentation, insulin, insulin resistance, thyroid function, electrolyte, inflammation (ESR/CRP), amylase, rheumatoid factor, calcium, phosphorus (bone metabolism), vitamin D (calcium absorption), syphilis, AIDS, tumor markers (e.g. pancreas/ colon/ liver/ ovary), storage, iron, total iron binding capacity, cervical cancer testing, mammography
Basic test A (Over age 45)	prognosis, mental health questionnaire, nutrition counseling, results counseling, physical measurement and body composition analysis, blood pressure, urine test, stool test (substimulation, parasites), vision test, ophthalmic measurement, ophthalmic test, hearing test, lung function test, electrocardiogram, chest scan, general blood test (blood disease, anemia, inflammation), general chemical test (liver function, alcohol interstellar function, jaundice, kidney function, gout); hepatitis (type A,B,C), hyperlipidemia (neutral fat, cholesterol), diabetes, glycolytic pigmentation, insulin, insulin resistance, thyroid function, electrolyte, inflammation (ESR/CRP), amylase, rheumatoid factor, calcium, phosphorus (bone metabolism), vitamin D (calcium absorption), syphilis, AIDS, tumor markers (e.g. pancreas/ colon/ liver/ ovary), storage, iron, total iron binding capacity, cervical cancer testing, mammography, bone density

5.6 Vaccines developed by country

By country, there are eight candidates for vaccines from China, five from Europe, four from the U.S., two from Russia, two from India and one from South Korea. Genexin DNA vaccine, Jinwon Life Sciences DNA vaccine, and SK Bioscience protein-based vaccine are being developed in Korea, but only Genexin has reached the 1/2 phase of clinical trials, while Jinwon Life Science and SK Bioscience are in full-time stages.

국내 코로나19 백신 후보 개발 현황 (기준: 2020년 8월 28일)

개발사-제조사	국가	종류	임상시험 단계			
			1상	1/2상	2상	3상
Inovio Pharmaceuticals / International Vaccine Institute	미국-한국	DNA				
Genexine	한국	DNA				
Vaxine Pty Ltd/Medytox	호주-한국	단백질				
GeneOne Life Science	한국	DNA	전임상			
SK Bioscience	한국	단백질	전임상			

VI.
MEC CHAIN PLATFORM

Accurate evaluation and verification of the medical institution

A reliable solution should be presented to eliminate the risk of infection through frequent blood collection , blood collection and contact in the process of self-identification through the voluntary participation of the test subjects. For this purpose, thorough prevention of the diagnostic inspection station itself should be carried out, and the storage and transportation process of samples and kits should be transparent and safe. The assessment of this process should be quantified to ensure users ' options by transparently disclosing the management indices of inspection stations.

Increased reliability of protecting personal health information

The medical information system centered on medical institutions is converted into a medical information system centered on medical consumers, i.e. the subjects. This creates an ideal Personal Health Record (PHR) platform with both transparency, openness and security. Thus, it aims to establish an information management and medical information system that enables reliable infection control tracking.

Social cost reduction

By issuing cryptocurrency , the medical information ecosystem centered on medical consumers will be established by collecting inspection records and health care data of examinees.

6.1 Platform Ecosystem



It is implemented in AOK blockchain platform – AOK Mainnet, which is released. In the years since the white paper was released and the mainnet launched, the speed and quality of the AOK blockchain shows the performance of many applications operating normally, and the blockchain network is operating soundly. With the recent rapid spread of infectious diseases, utilizing the AOK network with proven speed, functionality, and diverse applications for rapid deployment and effective service introduction of MEC-Chain will focus on the rapid development of MEC Test Service and active participation of Test Kit manufacturers and Test Service agencies as well as the flexibility and ease of users' test service infrastructure.

6.2 Platform features



The subjects shall prepare necessary preparations in advance in case they are required to receive a certificate of inspection for infection at the request of the local quarantine authorities when moving between countries. Subjects have to accomplish needed Test service and upload inspection results to the blockchain to be inquired using personal information, to provide information what way quarantine authorities desire. The information, blockchain data, equipment and services required by the peer inspector are as follows.

✓ Personal information: name, age, gender, nationality, passport number, contact information

✓ Inspection information: inspection date and time, inspection country, inspection type, inspection method, inspection hospital, inspection results, validity period of inspection

✓ Inspection kit information: kit manufacturer, kit type, validity period, certificate, contact information

✓ Blockchain data: Registration information, personal information, inspection information, inspection kit information

✓ Equipment: Smartphones and apps for blockchain data retrieval

Based on the above information, quarantine authorities can check the personal information of the quarantine subject and blockchain data presented by the person to check whether it is in accordance with the quarantine authorities' quarantine policy and use it for administrative disposition such as customs clearance and stay permits.

6. MEC CHAIN Platform

Before moving from one country to another, the examinee conducts necessary inspections at the hospital located in there residence , and the hospital enters and records all of the user 's personal information , inspection kit information , and inspection information on the blockchain . To this end, the hospital receives inspection kits from the kit manufacturer in advance and is authorized to access the blockchain before responding to the inspector's request for inspection. Where a pharmacy or self-inspection is conducted in addition to a hospital according to the type of inspection kit, the certification of inspection results and blockchain registration information shall be determined in accordance with the policy of the competent quarantine authority. It also responds to legitimate requests from other jurisdictions for information inquiries on the blockchain to the results of the examination of the subjects within the scope of the hospital's access to the information. Information, blockchain data, equipment and services required by the inspection agency are as follows.

✓ Hospital information: nationality, hospital name, location, information of the person in charge, contact information

✓ Inspection information: inspection type, inspection method, inspection experience, use inspection kit type

✓ Inspection kit information: kit manufacturer, kit type, validity period, certificate, contact information

✓ Blockchain data: Registration information, hospital information, inspection information, inspection kit information

✓ Equipment: PC or smartphone and app for blockchain data input and retrieval All inspection kit analysis equipment required for inspection (if separate equipment is required for analysis)

The inspection kit manufacturer supplies inspection kits and provides instructions on how to use the inspection kit by designating the inspection agency so that the inspection kit approved by the country of the location can be registered in the blockchain . The inspection kit manufacturer provides support for the inspection agency to respond to requests for legitimate information inquiry from the quarantine authorities as well as other local quarantine authorities. In addition, the inspection kit shall be certified to a sufficient extent in consideration of national or regional movements of the inspector. The results are registered and reflected in the inspection kit information. In addition, information on the types of diagnostic kits allowed under the quarantine policies of each country or region registered on the blockchain is inquired to register and reflect information on whether they are applicable to the subjects. Information, blockchain data, equipment and services required for this are as follows.

✓ Manufacturer information: nationality, manufacturer name, location, manager information, contact information

✓ Inspection kit information: type of kit, inspection method, certification, and country where inspection results are recognized

✓ Blockchain data: Registration information, manufacturer information, inspection kit information

✓ Equipment: PC for blockchain data input and retrieval, or all inspection kits for smartphones and apps (if separate equipment is required for analysis)

6.3 Token model

-Description of distribution and percentage of allocation of token



- Specify where the token is used and the plan for use

If the blood pack can be paid with a token, and the patient's data and the token holder's data exist in the hospital in advance. In case of emergency, blood can be supplied quickly

Easy medical examination, update the amount of oxygen, red blood cells, and white blood cells in the blood through your blood data to provide the data to the foundation, and the foundation pays tokens accordingly.

VII.
TEAM

Kim Jong-deok

- Seoul National University Political diplomacy
- 前)Samsung Electronics Staff Training Officer
- 前)Sirius CEO
- 現)辽宁晟世贸有限公司
- 現)MECRO CEO

Liu Hua

- California EMBA
- 前)CDCA Taiwan blockchain office cooperator
- 前)Financial Construction Society founding member
- 前)光大(Everbright)grup adviser on foreign financial investment
- 現)MECRO financial adviser

Cho Su-pyeong

- 清華大學 Global marketing
- 前)Baidu Marketing Team Leader
- 前)阿里巴巴 市场部经理
- 現)MECRO marketing director

Liu Hai-tao

- 南京大學 贸易专业
- 前)淘宝网 采购经理
- 現)MECRO 采购经理

VIII.
LEGAL DISCLAIMERS

8.1.

This white paper is intended to help you understand the MEC business. Investors are encouraged to purchase through exchanges or open sales channels at their own discretion.

본 백서는 MEC 사업의 이해를 돕기 위한 설명으로 투자자는 각자의 판단으로 거래소 또는 공개된 판매 루트를 통해 구입하기 바랍니다.

8.2.

MECRO, we do not guarantee return on investment to the buyer.

MECRO 는 구매자에게 투자수익을 보장하지 않습니다.

8.3.

MECRO, we do not guarantee the price after listing.

MECRO 는 상장 후 가격을 보장하지 않습니다.

8.4.

MECRO, we do not promise repurchase at the specified price

MECRO 는 지정된 가격으로 재구매를 약속하지 않습니다.

8.5.

MECRO, we do not operate branches or sales agents.

MECRO 는 지점 또는 영업 에이전트를 운영하지 않습니다.

8.6.

MECRO investors should make their own judgment that they are not in violation of the blockchain policy of each country.

MECRO 투자자는 각 국가의 블록 체인 정책을 위반하지 않는다는 자체 판단을 해야 합니다.

8.7.

Despite technical efforts, MECRO may incur investment losses depending on market conditions.

기술적인 노력에도 불구하고 MECRO 는 시장 상황에 따라 투자 손실이 발생할 수 있습니다.

8.8.

Despite our efforts, market instability or risk of market collapse is possible.

우리의 노력에도 불구하고 시장 불안정 또는 시장 붕괴 위험이 있습니다.

8.9.

MECRO main notice is to prioritize the presentation of the homepage.

MECRO 주요 공지는 홈페이지 프리젠테이션을 우선합니다.

8.10.

MECRO Other policies are announced on the official website.

MECRO 다른 정책은 공식 웹 사이트에 발표됩니다.

VIII.
LEGAL DISCLAIMERS

8.11.

MECRO is not a stock or any way of value guarantee.

MECRO 는 주식 또는 가치 보장 방법이 아닙니다.

8.12.

MECRO business model may change slightly depending on the agreement with the partner company.

MECRO 사업모델은 파트너 사와 협약하는 내용에 따라 일부 변경될 수 있습니다.

8.13.

Purchase of MECRO coin must be done by the buyer himself according to local law, AOK does not make any legal guarantee for purchase.

MECRO coin의 구입은 구매자가 현지 법률에 따라 스스로 진행해야 하며, AOK 는 구매에 대한 어떠한 법률적 보증을 하지 않습니다

8.14.

Among the contents mentioned in this white paper, the business model may change its brand or target in the process.

본 백서에 언급되는 내용 중 사업모델은 진행 과정에서 브랜드 또는 대상 등이 변경될 수 있습니다.

Published first in
2020.12.10

Mecro